Apimeds Competitors

Stocks . USA . 
Stock . Apimeds Pharmaceuticals US,
APUS Stock   1.73  0.05  2.98%   
Apimeds Pharmaceuticals competes with Talphera, MIRA Pharmaceuticals,, Scynexis, Milestone Scientific, and India Globalization; as well as few others. The company conducts business under Capital Markets sector and is part of Financials industry. Analyzing Apimeds Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Apimeds Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Apimeds Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Apimeds Pharmaceuticals competition on your existing holdings.
  
Build AI portfolio with Apimeds Stock
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Apimeds Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.091.7311.11
Details
Intrinsic
Valuation
LowRealHigh
0.081.6611.04
Details
Naive
Forecast
LowNextHigh
0.041.9011.28
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.272.163.06
Details

Apimeds Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Apimeds Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Apimeds and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Apimeds Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

IGC
+ 0.86
MLSS
ANTX
+ 0.83
IGC
ANTX
+ 0.82
MLSS
MLSS
+ 0.67
SCYX
MYO
+ 0.67
QTTB
MYO
+ 0.6
MLSS
  

High negative correlations

NXTC
- 0.65
MLSS
NXTC
- 0.61
ANTX
NXTC
- 0.61
IGC
SCYX
- 0.6
TLPH
NXTC
- 0.53
SCYX
MYO
- 0.48
POCI

Risk-Adjusted Indicators

There is a big difference between Apimeds Stock performing well and Apimeds Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Apimeds Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TLPH  4.42  0.47  0.08  0.69  5.50 
(5.01)
 9.57 
(8.66)
 34.39 
MIRA  3.34  0.45  0.09  1.68  4.19 
(3.48)
 8.78 
(6.29)
 46.36 
SCYX  2.27 (0.88) 0.00  84.87  0.00 
 0.00 
 2.67 
(4.76)
 26.67 
MLSS  3.95 (0.70) 0.00 (0.60) 0.00 
 0.00 
 8.33 
(9.52)
 28.05 
IGC  2.77 (0.44) 0.00 (0.23) 0.00 
 0.00 
 6.06 
(5.56)
 25.10 
POCI  1.76 (0.07) 0.00 (0.06) 0.00 
 0.00 
 3.57 
(3.23)
 27.89 
QTTB  6.06  1.31  0.18 (1.11) 6.03 
(6.92)
 10.64 
(10.73)
 85.16 
ANTX  2.02 (0.21) 0.00 (0.09) 0.00 
 0.00 
 3.20 
(4.24)
 21.89 
NXTC  6.02  1.56  0.21  0.93  6.19 
(6.89)
 15.65 
(8.76)
 60.54 
MYO  4.00 (0.07) 0.01  0.03  4.56 
(4.46)
 8.24 
(6.49)
 23.92 
All Fundamental Data

Apimeds Pharmaceuticals Competitive Analysis

The better you understand Apimeds Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Apimeds Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Apimeds Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
APUS TLPH MIRA SCYX MLSS IGC POCI QTTB ANTX NXTC
 2.98 
 1.73 
Apimeds
 3.74 
 1.11 
Talphera
 3.25 
 1.59 
MIRA
 4.92 
 0.58 
Scynexis
 6.45 
 0.29 
Milestone
 3.23 
 0.30 
India
 0.71 
 4.20 
Precision
 2.97 
 3.12 
Q32
 0.90 
 1.12 
AN2
 9.86 
 12.70 
NextCure
Market Volatility
(90 Days Market Risk)
Extremely Dangerous
Abnormally volatile
Extremely Dangerous
Dangerous
Out of control
Out of control
Moderately volatile
Very risky
Dangerous
Moderately volatile
Market Performance
(90 Days Performance)
Soft
Mild
Mild
Weakest
Weakest
Weakest
Weakest
Fair
Weakest
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Strong
Low
Risky
Low
Low
Small
Strong
Strong
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Buy
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Hold
Cautious Hold
Current Ratio
N/A
0.64
N/A
7.26
3.95
7.67
N/A
N/A
28.17
33.87
Net Asset
13.06 K
18.24 M
2.92 M
90.64 M
9.8 M
8.75 M
19.79 M
92.33 M
92.09 M
80.86 M
Profit Margin
N/A
N/A
N/A
N/A
-0.75
N/A
-0.28
N/A
N/A
N/A
EBITDA
(1.27 M)
(15.16 M)
(8.02 M)
(18.58 M)
(6.72 M)
(6.83 M)
(5.34 M)
(45.3 M)
3.23 M
(54.34 M)
Current Valuation
21.11 M
28.58 M
60.96 M
(9.94 M)
23.98 M
27.37 M
34.53 M
6.38 M
(31.23 M)
15.83 M
Price To Book
N/A
2.6
8.54
0.71
9.52
3.5
2.87
3.55
0.51
1.71
Operating Margin
N/A
N/A
N/A
-25.16
-0.48
-15.18
-0.24
N/A
N/A
N/A
Retained Earnings
(4.39 M)
(457.23 M)
(29.14 M)
(376.54 M)
(128.05 M)
(120.74 M)
(56.97 M)
(234.81 M)
(205.78 M)
(380.14 M)
Current Asset
N/A
9.04 M
N/A
48.44 M
10.74 M
3.84 M
N/A
N/A
N/A
46.99 M
Beta
N/A
0.25
1.81
1.36
0.93
0.25
0.3
N/A
-0.026
1.54
Number Of Employees
2
13
5
28
17
70
90
26
22
43
Shares Outstanding
11.58 M
46.61 M
41.88 M
41.97 M
78.63 M
92.87 M
7.71 M
12.3 M
27.4 M
3.51 M
Cash Flow From Operations
(733.53 K)
(12.68 M)
(5.56 M)
(24.01 M)
(2.92 M)
(4.79 M)
(3.55 M)
(67.72 M)
(49.26 M)
(40.8 M)
Total Debt
596.84 K
6.53 M
723.35 K
16.27 M
349.05 K
238 K
2.04 M
18.9 M
10.24 M
5.95 M
Return On Equity
N/A
-0.86
-1.23
-0.53
-1.36
-0.83
-0.58
-4.92
-0.46
-1.17
Return On Asset
-4.09
-0.31
-0.75
-0.29
-0.42
-0.5
-0.19
-0.33
-0.28
-0.58
Number Of Shares Shorted
3.22 K
2.17 M
273.55 K
1.16 M
1.87 M
292.75 K
36.41 K
295.19 K
37.59 K
20.61 K
Book Value Per Share
-0.22
0.42
0.19
0.87
0.032
0.088
1.42
-1.5
2.21
8.84
Current Liabilities
N/A
14.14 M
N/A
6.66 M
4.4 M
3.2 M
N/A
N/A
N/A
5.53 M
Total Asset
13.06 K
18.24 M
2.92 M
90.64 M
9.8 M
8.75 M
19.79 M
92.33 M
92.09 M
80.86 M
Short Ratio
0.01
6.6
0.84
1.83
0.67
0.44
1.25
4.03
0.47
0.38
Debt To Equity
N/A
0.17
N/A
2.8
0.046
0.026
N/A
N/A
N/A
0.01
Target Price
N/A
3.25
17.75
3.67
1.0
3.88
N/A
15.0
1.0
17.67
Shares Owned By Institutions
N/A
38.16
3.24
28.09
5.66
20.74
34.4
64.41
39.35
32.8
Market Capitalization
24.31 M
49.87 M
64.49 M
25.7 M
22.91 M
28.14 M
32.63 M
38.39 M
30.42 M
40.52 M
Price To Earning
N/A
N/A
N/A
-1.9
-6.39
-5.64
N/A
N/A
3.96
-25.44
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.03
Price To Sales
N/A
1781.15
N/A
8.77
2.57
25.44
1.51
N/A
N/A
9.52
Net Income
(1.39 M)
(13 M)
(7.85 M)
(21.29 M)
(4.71 M)
(7.12 M)
(5.78 M)
(47.73 M)
(51.32 M)
(55.65 M)
Earnings Per Share
-0.13
-0.38
-1.6
-0.51
-0.09
-0.07
-0.85
-3.4
-1.13
-24.19
Shares Owned By Insiders
81.96
28.41
16.65
2.16
22.6
8.11
28.06
6.48
25.38
20.16
Revenue
N/A
N/A
N/A
3.75 M
8.63 M
1.27 M
19.09 M
N/A
N/A
N/A
Working Capital
(1.01 M)
6.77 M
2.16 M
48.08 M
5.54 M
639 K
3.91 M
65.41 M
76.02 M
62.23 M
Cash And Equivalents
N/A
90.29 K
N/A
96.09 M
9.81 M
405 K
N/A
N/A
113.39 M
185.49 M
Cash Per Share
N/A
0.01
N/A
2.94
0.14
0.15
N/A
N/A
5.84
6.68
Gross Profit
N/A
(5.77 M)
N/A
2.93 M
6.42 M
511 K
3.23 M
(26.39 M)
N/A
(54.2 M)
Day Typical Price
1.84
1.13
1.57
0.59
0.3
0.3
4.2
3.06
1.12
12.4
Accumulation Distribution
0.19
0.14
0.044
0.0645
0.0645
0.0645
0.0189
0.073
0.0855
0.0732
Market Facilitation Index
0.4
0.17
0.07
0.04
0.02
0.02
0.08
0.23
0.1
0.93
Daily Balance Of Power
0.125
0.2353
0.7143
(0.75)
(1.00)
(0.50)
(0.38)
0.3913
0.1
1.225806
Period Momentum Indicator
0.05
0.04
0.05
(0.03)
(0.02)
(0.01)
(0.03)
0.09
0.01
1.14
Rate Of Daily Change
1.03
1.04
1.03
0.95
0.94
0.97
0.99
1.03
1.01
1.1
Day Median Price
1.9
1.14
1.56
0.6
0.3
0.3
4.2
3.04
1.12
12.25
Price Action Indicator
(0.15)
(0.01)
0.06
(0.04)
(0.02)
(0.01)
(0.01)
0.13
0.005
1.02
Coefficient Of Variation
2462.41
1186.26
1253.35
(515.80)
(859.54)
(1,118)
(11,849)
885.24
(2,562)
573.95
Mean Deviation
6.44
4.42
3.34
2.27
3.95
2.77
1.76
6.06
2.02
6.02
Jensen Alpha
0.2864
0.4653
0.4499
(0.88)
(0.70)
(0.44)
(0.07)
1.31
(0.21)
1.56
Total Risk Alpha
(0.41)
(0)
(0.03)
(1.26)
(1.08)
(0.67)
(0.30)
0.3217
(0.38)
0.8665
Sortino Ratio
0.0373
0.0756
0.0886
N/A
N/A
N/A
N/A
0.1752
N/A
0.2142
Downside Variance
70.15
35.36
21.19
N/A
N/A
N/A
N/A
45.96
N/A
56.34
Standard Deviation
9.38
6.14
5.97
4.5
5.36
3.84
3.13
11.12
3.02
9.62
Kurtosis
2.09
1.98
20.86
20.59
1.19
2.52
16.61
28.84
10.25
4.84
Potential Upside
15.05
9.57
8.78
2.67
8.33
6.06
3.57
10.64
3.2
15.65
Treynor Ratio
0.2563
0.6946
1.68
84.87
(0.60)
(0.23)
(0.06)
(1.11)
(0.09)
0.9296
Maximum Drawdown
53.45
34.39
46.36
26.67
28.05
25.1
27.89
85.16
21.89
60.54
Variance
87.94
37.75
35.6
20.26
28.71
14.76
9.79
123.69
9.13
92.57
Market Risk Adjusted Performance
0.2663
0.7046
1.69
84.88
(0.59)
(0.22)
(0.05)
(1.10)
(0.08)
0.9396
Risk Adjusted Performance
0.0377
0.068
0.0648
(0.13)
(0.07)
(0.05)
0.0018
0.0886
(0.02)
0.1315
Skewness
0.5131
0.2402
3.53
(2.07)
0.5637
0.5629
2.35
4.46
1.92
1.34
Semi Deviation
7.66
5.5
4.19
N/A
N/A
N/A
N/A
6.03
N/A
6.19
Information Ratio
0.0333
0.0732
0.0683
(0.21)
(0.13)
(0.11)
(0.03)
0.1068
(0.06)
0.1671
Value At Risk
(14.12)
(8.66)
(6.29)
(4.76)
(9.52)
(5.56)
(3.23)
(10.73)
(4.24)
(8.76)
Expected Short fall
(8.31)
(5.01)
(3.48)
N/A
N/A
N/A
N/A
(6.92)
N/A
(6.89)
Downside Deviation
8.38
5.95
4.6
N/A
N/A
N/A
N/A
6.78
N/A
7.51
Semi Variance
58.69
30.26
17.56
N/A
N/A
N/A
N/A
36.34
N/A
38.27

Apimeds Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Apimeds Pharmaceuticals Competition

Apimeds Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Apimeds Pharmaceuticals in relation to its competition. Apimeds Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Apimeds Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Apimeds Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Apimeds Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Apimeds Pharmaceuticals position

In addition to having Apimeds Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Banks Thematic Idea Now

Banks
Banks Theme
Large and small money and credit banks and credit services. The Banks theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Apimeds Stock Analysis

When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY